Biotech article - March 31, 2014
No preliminary investigation on Active Biotech
In the end of February Active Biotech was reported to the Swedish Economic Crime Authority, which has now decided not to precede with a preliminary investigation. The complaint to the Swedish Economic Crime Authority came from the organization INDEIN (Investigation Development for Investors). As reported in the web edition of the Swedish newspaper Sydsvenskan Active Biotech […]
Biotech article - February 27, 2014
Active Biotech reported for economic crime
The Lund-based pharmaceutical company has been reported to the Swedish Economic Crime Authority. Active Biotech is accused to have to misinformed their investors. Allegedly, the firm was aware of the that the MS drug Nerventra should have been stopped but concealed it. On January 25, the company share went down dramatically on the stock market. […]
Collaboration - January 27, 2014
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Teva Pharmaceutical Industries and Active Biotech has announced that both companies remain committed to the NERVENTRA(laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The […]
